Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Eric A, Raefsky"'
Autor:
Michel E. Kuzur, David R. Spigel, Kathleen Yost, Eric L. Raefsky, F. Anthony Greco, John D. Hainsworth, Sharlene Litchy, Kommor M
Publikováno v:
Cancer. 104:1992-1997
BACKGROUND The current study was performed to evaluate the activity of combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site. METHODS Patients with carcinoma of an unknown pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34a7d42b9504a19e1499385f6465099f
https://doi.org/10.1002/cncr.21416
https://doi.org/10.1002/cncr.21416
Autor:
John G. Kuhn, F. Anthony Greco, Sandra L. Greenwell, J. F. Patton, Howard A. Burris, Eric L. Raefsky, Dana S. Thompson, Margaret N. Baker, Charles E. McKay, John D. Hainsworth, Suzanne F. Jones
Publikováno v:
American Journal of Cancer. 3:317-324
To determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dosage of oral topotecan when administered in an intermittent schedule. Phase I study. Patients received a fixed dose of oral topotecan daily for 5 of 7 days fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::246ec7a984accf32df7e1343b396147b
https://doi.org/10.2165/00024669-200403050-00005
https://doi.org/10.2165/00024669-200403050-00005
Autor:
Ronald G. Steis, A. A. Meluch, F. Anthony Greco, H B A Lisa Morrissey, Eric L. Raefsky, James A. Butts, John D. Hainsworth
Publikováno v:
Cancer. 98:2192-2198
BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone-refractory prostate carcinoma. METHODS Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca784346b097006883ea04631fea12e4
https://doi.org/10.1002/cncr.11790
https://doi.org/10.1002/cncr.11790
Autor:
Howard A. Burris, Alejandro A. Inclan, Victor M. Priego, Eric L. Raefsky, John D. Hainsworth, Denise A. Yardley
Publikováno v:
Breast cancer research and treatment. 148(3)
Amrubicin is a synthetic anthracycline which has been shown in preclinical studies to have broad-spectrum anti-tumor activity and a lower potential for cardiotoxicity as compared to doxorubicin. We conducted a phase 1/2 trial of single-agent amrubici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94d66414717ecc0ddf8618279fa9fa1
https://pubmed.ncbi.nlm.nih.gov/25374098
https://pubmed.ncbi.nlm.nih.gov/25374098
Autor:
Joan B. Erland, Lisa H. Morrissey, Steven W. Smith, F. Anthony Greco, David Rinaldi, Howard A. Burris, John D. Hainsworth, J. R. Gray, Charles Dobbs, Sharlene Litchy, Eric L. Raefsky
Publikováno v:
Cancer. 92:2142-2147
BACKGROUND The objective of this study was to determine the feasibility and toxicity of paclitaxel and carboplatin given in the adjuvant setting alone for patients with resected Stage IB disease and combined with radiotherapy for patients with resect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c0964614e1cdad47a281a69b1c35213
https://doi.org/10.1002/1097-0142(20011015)92:8<2142::aid-cncr1556>3.0.co
https://doi.org/10.1002/1097-0142(20011015)92:8<2142::aid-cncr1556>3.0.co
Autor:
David R. Spigel, Denise A. Yardley, N. W. Peacock, Jeffrey Patton, John D. Hainsworth, Eric L. Raefsky, F. Anthony Greco, C. Farley, Howard A. Burris
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(1)
Purpose Tracheoesophageal fistulae are rare complications of thoracic cancers and their treatments. Novel antiangiogenic agents in cancer treatment such as bevacizumab potentially impact wound healing and may contribute to tracheoesophageal fistula d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b1d54f4c201fc74f58d32ac8adb40d
https://pubmed.ncbi.nlm.nih.gov/19901100
https://pubmed.ncbi.nlm.nih.gov/19901100
Autor:
Eric L. Raefsky, Elizabeth R. Vazquez, F. Anthony Greco, David R. Spigel, James D. Bearden, John D. Hainsworth, Ruben A. Saez
Publikováno v:
Cancer. 112(6)
BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b860d606f7245859572f6536a63ad147
https://pubmed.ncbi.nlm.nih.gov/18189296
https://pubmed.ncbi.nlm.nih.gov/18189296
Autor:
F. Anthony Greco, Noel T. Willcutt, Eric L. Raefsky, Aurelia F. Beschorner, Howard A. Burris, Suzanne F. Jones, Fernando T. Miranda, Victor G. Gian, Glyndon Kennerly, John D. Hainsworth
Publikováno v:
Cancer. 104(9)
BACKGROUND The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis. MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6916a209e973d4a48663865509ea50
https://pubmed.ncbi.nlm.nih.gov/16134182
https://pubmed.ncbi.nlm.nih.gov/16134182
Autor:
Suzanne F, Jones, Howard A, Burris, John D, Hainsworth, Denise A, Yardley, Eric A, Raefsky, Fernando T, Miranda, Michel E, Kuzur, Noel T, Willcutt, Melissa B, White, F Anthony, Greco
Publikováno v:
Oncology (Williston Park, N.Y.). 17(5 Suppl 5)
A phase I study of carboplatin (Paraplatin) administered in two different dosing schedules (single dose every 4 weeks and weekly dosing) in combination with weekly irinotecan (CPT-11, Camptosar) was conducted in patients with relapsed or refractory a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7a7e9dea5b572c4471128194a467e3f
https://pubmed.ncbi.nlm.nih.gov/12800605
https://pubmed.ncbi.nlm.nih.gov/12800605
Autor:
Eric L. Raefsky, Cecile Bulanhagui, F. Anthony Greco, Suzanne F. Jones, Howard A. Burris, Sharon Calvert, Valerie Johnson, David Lebwohl, John D. Hainsworth, Dana S. Thompson
Publikováno v:
Investigational new drugs. 20(1)
This phase I study was conducted to determine the dose limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of JM-216 and paclitaxel. Patients received paclitaxel intravenously over one hour on day 1 of each c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59f5cbf3137e4aba454aac764c9362eb
https://pubmed.ncbi.nlm.nih.gov/12008664
https://pubmed.ncbi.nlm.nih.gov/12008664